RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
- According to Martin F et al, AKT is highly phosphorylated in phenochromocytoma but not
in benign adrenocortical tumors.
- In nonfunctioning carcinoid, the PI3K/AKT/mTOR pathway is activated.
- Although mTOR is clearly an attractive therapeutic target in tumor, no clinical study on
mTOR inhibition by RAD001 have been conducted in pheochromocytoma or extra-adrenal
paraganglioma or non-functioning carcinoid.
- So we design this phase II study of RAD001 in pheochromocytoma or extra-adrenal
paraganglioma or non-functioning carcinoid to evaluate the efficacy of RAD001 in this
orphan disease.